Langmuir (1996) 12:134350
Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
This product page is structured to support compound discovery, product comparison, batch verification, and professional research workflow planning
A: Yes, it can be used daily for a short duration as prescribed by a healthcare professional
Signs and symptoms Loose joints Joint pain Stretchy, velvety skin Fragile skin Abnormal scar formation Complications Aortic dissection Joint dislocations Scoliosis Chronic pain Early osteoarthritis Management Obstetrical anesthesia Difficult management, requires multidisciplinary effort High risk of preterm labor, uterine rupture, and hemorrhage Neuraxial anesthesia is relatively contraindicated, may need general anesthesia If vascular subtype recommendations are termination of pregnancy or Cesarean section before 32 weeks Keep in mind Avoid ambulatory surgery in EDS patients Be aware of typical EDS-related emergency-like situations such as difficult airway status, bleeding risks, and organ rupture in specific subtypes Suggested reading Malfait F, Francomano C, Byers P, et al